Louisville Medicine Volume 65, Issue 11 - Page 17

FEATURE TABLE 2 VACCINE EFFICACY OF RZV AGAINST HERPES ZOSTER INFECTION (7) # # confirmed cases Follow up Person yrs. Rate HZ Per 1000 Person yrs. Vaccine efficacy VE% (95% Cl) 0.3 7415 210 23170.5 9.1 97.2 (93.7- 99.0) 11,161.3 0.3 3525 87 11,134.7 7.8 96.9 (89.6-99.3) 2 7007.9 0.3 2166 75 6952.7 10.8 97.4 (90.1-99.7) 1 5129.7 0.2 1724 48 5083.0 9.4 91.3 (86.8-94.5) # # confirmed cases Follow up Persons yrs. Rate of HZ Per 1000 Person yrs. All persons 7344 6 23,297.0 50-59 3492 3 60-69 2141 70 1711 Age Group Two doses VE = Vaccine Efficacy, P = < 0.001 for all comparisons Herpes Zoster • About 90% of HZ episodes associated with pain • Treatment: antivirals reduce duration of rash and pain 1 PHN • Pain at least 90 days following resolution of rash 2 • Treatment: minimal or no efficacy. Side effects, especially in elderly Cohen et al, NEJM 2013, 2. Johnson et al, NEJM 2014 “My PHN is worse than my cancer and chemotherapy ... [it] has made me depressed and suicidal in the past” APRIL 2018 15